Beijing-Based BeiGene Study Of PD-1 Antibody For Patients With Relapsed Or Refractory Hodgkin Lymphoma Underway

Beijing-based BeiGene has dosed their first patient with refractory classical Hodgkin lymphoma — or cHL — in their Phase I PD-1 checkpoint trial of the drug BGB-A317 in a pivotal study which started less then four months ago.